Brief: Alpine Immune Sciences Terminates Enrollment Of Davoceticept Clinical Studies

Alpine Immune Sciences

24/10/2022 12:42

Oct 24 (Reuters) - Alpine Immune Sciences Inc  ALPN.O :
    * ALPINE IMMUNE SCIENCES TERMINATES ENROLLMENT OF
DAVOCETICEPT
CLINICAL STUDIES (NEON-1 AND NEON-2)
    * ALPINE IMMUNE SCIENCES- PRIMARY FOCUS WILL BE PURSUIT OF
EXPEDITED DEVELOPMENT PLANS FOR ALPN-303 IN MULTIPLE AUTOIMMUNE
AND INFLAMMATORY INDICATIONS
    * ALPINE IMMUNE SCIENCES INC - DECISION TO TERMINATE
ENROLLMENT IN
DAVOCETICEPT STUDIES WAS MADE IN INTEREST OF PATIENT SAFETY
    * ALPINE IMMUNE SCIENCES INC - CONDUCTING AN ONGOING,
COMPREHENSIVE ASSESSMENT OF ALL NEON STUDY PARTICIPANTS
    * ALPINE IMMUNE SCIENCES -  DECISION TO TERMINATE ENROLLMENT
AFTER
CO WAS NOTIFIED OF A SECOND DEATH IN NEON-2 STUDY, ATTRIBUTED TO
CARDIOGENIC SHOCK

Source text for Eikon:  ID:nBw86PG3Ra 
Further company coverage:  ALPN.O 
 ((Reuters.Briefs@thomsonreuters.com;))